Evolving therapies This review explores novel treatments for bullous pemphigoid (BP), focusing on innovative approaches targeting various immune pathways.

Promising options Rituximab, dupilumab, eosinophil-targeted molecules, omalizumab, complement inhibitors, interleukin (IL)-17 and IL-23 inhibitors, neonatal Fc receptor antagonists, topical therapies, and Janus kinase inhibitors are among the promising therapies being investigated for the management of BP.

Need for further research Despite these potential treatments, controlled clinical trials are crucial to establish the efficacy, safety, and optimal dosing regimens for managing BP, aiming to improve outcomes while minimizing systemic steroid use and associated toxicities.